Search

everythinglearnresearchcommunity

for

Search:↓

All four treatments for early rheumatoid arthritis had similar safety profiles.

All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.

Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.

Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.

The 1298CC genotype in RA patients leads to higher methotrexate toxicity, while the 1298AA genotype results in better treatment response.

A woman with rheumatoid arthritis had a unique type of scarring hair loss not caused by infection, requiring early treatment to avoid permanent hair loss.

Targeting CD200 could be a new treatment for rheumatoid arthritis.

Most skin rashes in rheumatoid arthritis patients were not caused by their medication, and careful evaluation allowed most to keep taking their beneficial treatment.

Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

A patient lost all their hair while on rheumatoid arthritis medication.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Oral tofacitinib successfully treated total body hair loss in one patient.

Managing multiple autoimmune diseases in one patient is very challenging.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Weekly 5 mg folate is enough to prevent methotrexate toxicity in rheumatoid arthritis patients.

An arthritis drug helped a person with severe hair loss regrow their hair.

A 29-year-old woman with symptoms of both lupus and rheumatoid arthritis improved with specific medications.

Leflunomide is effective for rheumatoid arthritis but has significant side effects.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

The CDC reports 23 measles cases in unvaccinated US kids, new treatments for eosinophilic esophagitis and osteopenia are approved, poor sleep may cause migraines, atopic dermatitis could lead to asthma, migraines might increase Crohn's disease risk, cancer may raise heart disease risk, gout is linked to prostate issues, Cabo Verde is malaria-free, social factors and vitamin D affect dementia risk, smoking increases hair loss risk, certain drugs might lower thyroid disease risk in arthritis, noma is a neglected disease, and meal timing could impact heart health.

Early treatment of EPDS can improve outcomes and reduce recurrence risk.